Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Fund moves › Charles River Laboratories › FMR LLC now owns 7% of CRL as a passive investor Fund moves
Why it stands out A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Date of the event that required the filing Mar 31, 2026
Reporting period Not applicable
Filed with the SEC May 6, 2026 passive 5% holder
Context Change vs prior quarter Undefined
Compared with the manager's prior 13F
Tracked managers with the same change NaN
For the same quarter
0000315066-26-001147
Data quality Verified: identifiers matched exactly
Around the same time Insider filing
Traded Jun 2 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded May 29 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded May 29 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Jan 20, 2026 Federal contract · $1.9M obligated Department of Health and Human Services awarded Charles River Laboratories: $1.92M obligated to date Feb 10, 2026 5% stake Wellington Management Group LLP reported a passive stake (13G) of 3.6% Feb 12, 2026 5% stake Invesco Ltd. reported a passive stake (13G) of 5.5% Feb 18, 2026 Company filing · Form 8-K · Executive change Changed a top executive or board member “On February 18, 2026, the Company announced the appointment of Glenn Coleman as its Corporate Executive Vice President and Chief Financial Officer. Mr. Coleman will join the company with a tentative start date of April 6, 2026.” Feb 18, 2026 Company filing · Form 8-K · Results Reported its results Feb 25, 2026 Federal contract · $936K obligated Department of Health and Human Services awarded Charles River Laboratories: $936K obligated to date Mar 3, 2026 Insider · First insider buy since Feb 2025 Officer purchased ~$4.4K of CRL shares in the open market Mar 26, 2026 5% stake The Vanguard Group reported a passive stake (13G) What came next Apr 29, 2026 5% stake Vanguard Capital Management reported a passive stake (13G) of 7.4% May 5, 2026 Company filing · Form 8-K · Executive change, Shareholder vote Changed a top executive or board member, and held a shareholder vote “On May 5, 2026, Charles River Laboratories International, Inc. (the “Company”) held its 2026 annual meeting of shareholders (the “Annual Meeting”). As further discussed below, at the Annual Meeting, the shareholders of the Company approved the Company’s 2026 Long-Term Incentive Plan (the “2026 Incentive Plan”).” May 6, 2026 5% stake FMR LLC reported a passive stake (13G) of 7.0%